Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Tuberculosis

  Free Subscription


21.01.2019

2 Am J Respir Crit Care Med
2 Emerg Infect Dis
1 Eur Respir J
1 Int J Tuberc Lung Dis
1 J Bacteriol
2 Lancet Glob Health
2 Lancet Respir Med
4 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Respir Crit Care Med

  1. TE BRAKE LHM, Boeree MJ, Aarnoutse RE
    Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201811-2101.
    PubMed     Text format    

  2. VELASQUEZ GE, Brooks MB, Coit JM, Sanchez Garavito E, et al
    Reply to: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2019 Jan 15. doi: 10.1164/rccm.201812-2281.
    PubMed     Text format    


    Emerg Infect Dis

  3. LOUTET MG, Davidson JA, Brown T, Dedicoat M, et al
    Acquired Resistance to Antituberculosis Drugs in England, Wales, and Northern Ireland, 2000-2015.
    Emerg Infect Dis. 2018;24:524-533.
    PubMed     Text format     Abstract available

  4. KLOTZ D, Barth SA, Baumgartner W, Hewicker-Trautwein M, et al
    Mycobacterium avium subsp. hominissuis Infection in a Domestic Rabbit, Germany.
    Emerg Infect Dis. 2018;24:596-598.
    PubMed     Text format     Abstract available


    Eur Respir J

  5. ABUBAKAR I, Lipman M
    Reducing loss to follow-up during treatment for drug-resistant tuberculosis.
    Eur Respir J. 2019;53.
    PubMed     Text format    


    Int J Tuberc Lung Dis

  6. DUDNYK A, Chesov D, Lange C
    Mission impossible: the End TB strategy.
    Int J Tuberc Lung Dis. 2018;22:121-122.
    PubMed     Text format    


    J Bacteriol

  7. MISRA R, Menon D, Arora G, Virmani R, et al
    Tuning the Mycobacterium tuberculosis alternative sigma factor SigF through the multidomain regulator Rv1364c and osmosensory kinase, protein kinase D.
    J Bacteriol. 2019 Jan 14. pii: JB.00725-18. doi: 10.1128/JB.00725.
    PubMed     Text format     Abstract available


    Lancet Glob Health

  8. HARRIS RC, Sumner T, Knight GM, Evans T, et al
    Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling study.
    Lancet Glob Health. 2019 Jan 7. pii: S2214-109X(18)30452.
    PubMed     Text format     Abstract available

  9. WANG Y, Wang W
    Importance of tuberculosis vaccination targeting older people in China.
    Lancet Glob Health. 2019 Jan 7. pii: S2214-109X(18)30480.
    PubMed     Text format    


    Lancet Respir Med

  10. CENTIS R, Sotgiu G, Migliori GB
    Delamanid: does it have a role in tuberculosis treatment?
    Lancet Respir Med. 2019 Jan 7. pii: S2213-2600(18)30455.
    PubMed     Text format    

  11. VON GROOTE-BIDLINGMAIER F, Patientia R, Sanchez E, Balanag V Jr, et al
    Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
    Lancet Respir Med. 2019 Jan 7. pii: S2213-2600(18)30426.
    PubMed     Text format     Abstract available


    PLoS One

  12. OLLINGER J, Kumar A, Roberts DM, Bailey MA, et al
    A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis.
    PLoS One. 2019;14:e0205479.
    PubMed     Text format     Abstract available


  13. Correction: Response to anti-tuberculosis treatment by people over age 60 in Kampala, Uganda.
    PLoS One. 2019;14:e0210769.
    PubMed     Text format     Abstract available

  14. CHEN YT, Kuo SC, Chao PW, Chang YY, et al
    Use of lipid-lowering agents is not associated with improved outcomes for tuberculosis patients on standard-course therapy: A population-based cohort study.
    PLoS One. 2019;14:e0210479.
    PubMed     Text format     Abstract available

  15. THAKUR A, Andrea A, Mikkelsen H, Woodworth JS, et al
    Targeting the Mincle and TLR3 receptor using the dual agonist cationic adjuvant formulation 9 (CAF09) induces humoral and polyfunctional memory T cell responses in calves.
    PLoS One. 2018;13:e0201253.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: